Your browser doesn't support javascript.
Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
Ojeda, Diego S; Gonzalez Lopez Ledesma, María Mora; Pallarés, Horacio M; Costa Navarro, Guadalupe S; Sanchez, Lautaro; Perazzi, Beatriz; Villordo, Sergio M; Alvarez, Diego E; Echavarria, Marcela; Oguntuyo, Kasopefoluwa Y; Stevens, Christian S; Lee, Benhur; Carradori, Jorge; Caramelo, Julio J; Yanovsky, Marcelo J; Gamarnik, Andrea V.
  • Ojeda DS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Gonzalez Lopez Ledesma MM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Pallarés HM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Costa Navarro GS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Sanchez L; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Perazzi B; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Hospital de Clínicas José de San Martin, Departamento de Bioquímica Clínica, Buenos Aires, Argentina.
  • Villordo SM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Alvarez DE; Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín-CONICET, Argentina.
  • Echavarria M; Unidad de Virologia, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC-CONICET), Argentina.
  • Oguntuyo KY; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Stevens CS; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Lee B; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Carradori J; Laboratorio Lemos S.R.L, Buenos Aires, Argentina.
  • Caramelo JJ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Yanovsky MJ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Gamarnik AV; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
PLoS Pathog ; 17(1): e1009161, 2021 01.
Article in English | MEDLINE | ID: covidwho-1388959
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
We report the emergency development and application of a robust serologic test to evaluate acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays, COVIDAR IgG and IgM, which were produced and provided for free to health authorities, private and public health institutions and nursing homes, use a combination of a trimer stabilized spike protein and the receptor binding domain (RBD) in a single enzyme-linked immunosorbent assay (ELISA) plate. Over half million tests have already been distributed to detect and quantify antibodies for multiple purposes, including assessment of immune responses in hospitalized patients and large seroprevalence studies in neighborhoods, slums and health care workers, which resulted in a powerful tool for asymptomatic detection and policy making in the country. Analysis of antibody levels and longitudinal studies of symptomatic and asymptomatic SARS-CoV-2 infections in over one thousand patient samples provided insightful information about IgM and IgG seroconversion time and kinetics, and IgM waning profiles. At least 35% of patients showed seroconversion within 7 days, and 95% within 45 days of symptoms onset, with simultaneous or close sequential IgM and IgG detection. Longitudinal studies of asymptomatic cases showed a wide range of antibody responses with median levels below those observed in symptomatic patients. Regarding convalescent plasma applications, a protocol was standardized for the assessment of end point IgG antibody titers with COVIDAR with more than 500 plasma donors. The protocol showed a positive correlation with neutralizing antibody titers, and was used for clinical trials and therapies across the country. Using this protocol, about 80% of convalescent donor plasmas were potentially suitable for therapies. Here, we demonstrate the importance of providing a robust and specific serologic assay for generating new information about antibody kinetics in infected individuals and mitigation policies to cope with pandemic needs.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: South America / Argentina Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: JOURNAL.PPAT.1009161

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: South America / Argentina Language: English Journal: PLoS Pathog Year: 2021 Document Type: Article Affiliation country: JOURNAL.PPAT.1009161